The Effect and Safety of the Antithrombotic Therapies in Patients with Atrial Fibrillation and CHADS(2) Score 1
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Byung Ho | - |
dc.contributor.author | Park, Jae Seok | - |
dc.contributor.author | Park, Jae Hyung | - |
dc.contributor.author | Park, Jong Seung | - |
dc.contributor.author | Kwak, Jae Jin | - |
dc.contributor.author | Hwang, Eui Seock | - |
dc.contributor.author | Kim, Sook Kyoung | - |
dc.contributor.author | Choi, Dong Hoon | - |
dc.contributor.author | Kim, Young-Hoon | - |
dc.contributor.author | Pak, Hui-Nam | - |
dc.date.accessioned | 2021-09-08T03:21:54Z | - |
dc.date.available | 2021-09-08T03:21:54Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2010-05 | - |
dc.identifier.issn | 1045-3873 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/116490 | - |
dc.description.abstract | Methods and Results: Among 1,502 patients (mean 62.4 +/- 13.8 years old, male 65.4%) who were treated for nonvalvular AF without previous stroke, the number of patients with CHADS(2) score 1 was 422 (62.9 +/- 10.7 years old, male 290 [68.7%]) and their antithrombotic therapies were as follows: warfarin (n = 143), aspirin (n = 124), other antiplatelet (n = 45), and no antithrombosis (none: n = 110). We reviewed the incidences of ischemic stroke, mortality, and bleeding complications during the follow-up period. Results were: (1) during 22.3 +/- 17.8 months of follow-up, the incidence of ischemic stroke was significantly lower in warfarin (6 patients, 4.2%, mean international normalized ratio [INR] 2.0 +/- 0.5 IU) than in aspirin (16 patients, 12.9%, P = 0.008) than none (23 patients, 20.9%, P < 0.001) without differences in all-cause mortality. (2) The incidence of major bleeding (decrease in hemoglobin >= 2 g/dL, requiring hospitalization or red blood cell transfusion >= 2 pints) was not different between warfarin (2.1%) and aspirin (0.8%, P = NS), but minor bleeding was more common in warfarin (10.5%) than in aspirin (2.4%, P = 0.007). Conclusion: In AF patients with CHADS(2) score 1, warfarin was better to prevent ischemic stroke than aspirin without increasing the incidence of major bleeding complications. However, the incidence of minor bleeding was higher in the warfarin group than the aspirin group. (J Cardiovasc Electrophysiol, Vol. 21, pp. 501-507, May 2010). | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | MODIFIED RANKIN SCALE | - |
dc.subject | ORAL ANTICOAGULATION | - |
dc.subject | STROKE PREVENTION | - |
dc.subject | SINUS RHYTHM | - |
dc.subject | ASPIRIN | - |
dc.subject | RISK | - |
dc.subject | IRBESARTAN | - |
dc.subject | INTENSITY | - |
dc.subject | WARFARIN | - |
dc.subject | MAINTAIN | - |
dc.title | The Effect and Safety of the Antithrombotic Therapies in Patients with Atrial Fibrillation and CHADS(2) Score 1 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Young-Hoon | - |
dc.identifier.doi | 10.1111/j.1540-8167.2009.01661.x | - |
dc.identifier.scopusid | 2-s2.0-77951154057 | - |
dc.identifier.wosid | 000276792100003 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, v.21, no.5, pp.501 - 507 | - |
dc.relation.isPartOf | JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY | - |
dc.citation.title | JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY | - |
dc.citation.volume | 21 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 501 | - |
dc.citation.endPage | 507 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | MODIFIED RANKIN SCALE | - |
dc.subject.keywordPlus | ORAL ANTICOAGULATION | - |
dc.subject.keywordPlus | STROKE PREVENTION | - |
dc.subject.keywordPlus | SINUS RHYTHM | - |
dc.subject.keywordPlus | ASPIRIN | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | IRBESARTAN | - |
dc.subject.keywordPlus | INTENSITY | - |
dc.subject.keywordPlus | WARFARIN | - |
dc.subject.keywordPlus | MAINTAIN | - |
dc.subject.keywordAuthor | atrial fibrillation | - |
dc.subject.keywordAuthor | antithrombotic therapy | - |
dc.subject.keywordAuthor | stroke | - |
dc.subject.keywordAuthor | warfarin | - |
dc.subject.keywordAuthor | aspirin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.